An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 213703
Company: MSN

Products on ANDA 213703

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
CANGRELOR	CANGRELOR	50MG/VIAL	POWDER;INTRAVENOUS	Prescription	AP	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 213703

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
06/04/2026	ORIG-1	Approval		STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213703Orig1s000TAltr.pdf

Therapeutic Equivalents for ANDA 213703

CANGRELOR

POWDER;INTRAVENOUS; 50MG/VIAL
TE Code = AP

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
CANGRELOR	CANGRELOR	50MG/VIAL	POWDER;INTRAVENOUS	Prescription	No	AP	213551	GLAND
CANGRELOR	CANGRELOR	50MG/VIAL	POWDER;INTRAVENOUS	Prescription	No	AP	213703	MSN
KENGREAL	CANGRELOR	50MG/VIAL	POWDER;INTRAVENOUS	Prescription	Yes	AP	204958	CHIESI

Top